8-K: Nektar Therapeutics: Rezpegaldesleukin Shows Promise in Alopecia Areata Study

Nektar Therapeutics announced 52-week topline results from the REZOLVE-AA study extension, showing continued hair regrowth in patients with severe-to-very-severe alopecia areata treated with rezpegaldesleukin.

Summary

• Nektar Therapeutics reported 52-week topline results from the blinded 16-week treatment extension of its REZOLVE-AA study for rezpegaldesleukin in severe-to-very-severe alopecia areata (AA).
• The study involved 92 patients, with 31 continuing into the extension period.
• From week 36 to week 52, 29% of patients on the low dose (18 g/kg) and 31% on the high dose (24 g/kg) achieved new SALT Score 20 responses, compared to none in the placebo arm.
• At week 52, overall study population showed 25.8% (low dose) and 27.6% (high dose) achieving SALT Score 20, versus 6.7% for placebo (p=0.049).
• Higher proportions achieved SALT Score 30 (30.2% low dose, 35.0% high dose vs. 8.4% placebo, p=0.023) and SALT50 (37.7% low dose, 38.8% high dose vs. 13.6% placebo).
• The safety profile remained favorable, consistent with prior studies, with most adverse events being mild-to-moderate.
• 94% of patients in the extension completed 52 weeks of treatment, with no discontinuations due to adverse events during the extension.
• The company plans to present these results at a medical conference in 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with promising efficacy and a favorable safety profile for rezpegaldesleukin in alopecia areata, supporting its advancement into late-stage development.

Positives

• Continued deepening of hair regrowth responses observed through week 52 in the treatment extension period.
• Significant percentage of patients achieved SALT Score 20 (80%+ scalp coverage) and SALT Score 30 (70%+ scalp coverage) in rezpegaldesleukin arms compared to placebo.
• Favorable safety and tolerability profile maintained with 52 weeks of twice-monthly dosing.
• High completion rate (94%) in the treatment extension period with no discontinuations due to adverse events.
• No patients discontinued treatment due to injection site reactions (ISRs), which were mostly mild to moderate.
• The results support the advancement of rezpegaldesleukin into late-stage development for alopecia areata.
• Rezpegaldesleukin demonstrated a differentiated safety profile compared to JAK inhibitors, avoiding associated boxed warnings and extensive lab monitoring.

Negatives

• While statistically significant, the absolute percentage of patients achieving SALT Score 20 (25.8% and 27.6%) may still be considered moderate by some.
• The study involved a relatively small number of patients (31) in the extension period.
• The p-value for SALT Score 20 response (0.049) is close to the typical significance threshold.

Risks

• Rezpegaldesleukin is an investigational agent, and future clinical studies may yield negative safety or efficacy findings.
• The risk of failure in clinical development is high and can occur at any stage prior to regulatory approval.
• Timing of clinical trials and data availability may be delayed due to regulatory hurdles, patient enrollment, manufacturing, or evolving regulatory requirements.
• A Fast Track designation does not guarantee marketing approval.
• The company's success is heavily dependent on the successful development and commercialization of rezpegaldesleukin.
• Potential for negative safety and efficacy findings in future clinical studies.
• Competition from existing and emerging treatments for alopecia areata.

Future Outlook

Nektar Therapeutics plans to submit the REZOLVE-AA results for presentation at a medical conference in 2026. The company is also planning to conduct an End of Phase 2 meeting with the FDA in Q2 2026 to align on the Phase 3 registrational strategy for alopecia areata. Additional data from the REZOLVE-AA study (24-week off-treatment data) are expected in Q4 2026. The company anticipates initiating the ZENITH-AD Phase 3 program in atopic dermatitis in June/July 2026 and expects initial data from the Type 1 diabetes study in 2027.

Management Comments

• "The new SALT20 responders in this set of patients treated out to 52 weeks reflect how the T regulatory cell mechanism of REZPEG can have more clinical benefit over time, a phenomenon the investigators observed in the Phase 2 study in atopic dermatitis as well," said Jonathan Silverberg, MD, PhD, MPH.
• "Given the prescribing and safety limitations of JAK inhibitors, these new data point to the potential for rezpegaldesleukin to be the first safe and effective biologic in alopecia areata, which may completely transform the management of the disease."
• "These extension treatment data to 52 weeks demonstrate the potential of rezpegaldesleukin to deliver truly meaningful clinical outcomes for patients with severe-to-very-severe alopecia areata," said David Rosmarin, MD.
• "We are in need of a new mechanism for a first-line systemic treatment option as an alternative to the class of agents currently approved for patients. The safety profile combined with a significantly higher number of patients achieving SALT Score 20 with continued treatment reinforce that this first-in-class Treg mechanism could emerge as the treatment of choice for patients with alopecia areata, including also those with moderate disease."
• "We are excited that rezpegaldesleukin has now demonstrated great promise in two large immune-mediated disease settings as we advance into registrational trials," said Howard W. Robin, President and CEO of Nektar Therapeutics.
• "As a completely novel mechanism of action in immunology which leverages T regulatory cell biology, we've shown that rezpegaldesleukin could offer compelling efficacy and safety advantages for patients battling various auto-immune conditions."

Industry Context

StockSavvy.ai notes that the results from Nektar Therapeutics' REZOLVE-AA study are significant in the context of the alopecia areata market, which is currently dominated by JAK inhibitors. The demonstrated efficacy and favorable safety profile of rezpegaldesleukin, a novel Treg biologic, position it as a potential first-in-class alternative, addressing the unmet need for safer and more durable treatments.

Comparison to Industry Standards

• The study's primary endpoint for registrational trials is SALT Score 20, defined as 80% or more scalp coverage. The rezpegaldesleukin arms achieved 25.8% (low dose) and 27.6% (high dose) at week 52, compared to 6.7% for placebo.
• For SALT Score 30 (70% or more scalp coverage), the rezpegaldesleukin arms achieved 30.2% (low dose) and 35.0% (high dose) at week 52, compared to 8.4% for placebo.
• Cross-trial comparisons suggest rezpegaldesleukin's efficacy in achieving SALT Score 20 and SALT Score 30 may be comparable or superior to some JAK inhibitors, particularly considering its differentiated safety profile.
• The safety profile, with a low incidence of mild-to-moderate adverse events and no discontinuations due to adverse events in the extension, contrasts favorably with the boxed warnings and monitoring requirements associated with JAK inhibitors like Olumiant and Rinvoq.

Stakeholder Impact

• Shareholders: Positive impact due to progress in clinical development of a promising drug candidate, potentially increasing future value.
• Patients with Alopecia Areata: Potential for a new, safer, and effective treatment option that could significantly improve quality of life.
• Healthcare Providers: May have a new therapeutic option with a differentiated safety profile compared to current treatments, simplifying patient management.
• Competitors: Increased competitive pressure as rezpegaldesleukin advances, potentially impacting market share for existing alopecia areata treatments.

Next Steps

• Submit REZOLVE-AA results for presentation at a medical conference in 2026.
• Conduct End of Phase 2 meeting with FDA in Q2 2026 to align on Phase 3 registrational strategy for Alopecia Areata.
• Initiate ZENITH-AD Phase 3 program in patients with moderate-to-severe atopic dermatitis in June/July 2026.
• Read out additional data from REZOLVE-AA Study (24-week off treatment data) in Q4 2026.
• Read out additional data from REZOLVE-AD Study (52-week off treatment data) in Q1 2027.
• Initiate proof-of-concept study for a potential new indication for REZPEG in 2H 2026.

Key Dates

Recommendation

The results are encouraging and support the advancement of rezpegaldesleukin, but it remains an investigational drug. While the efficacy and safety profile are promising, especially compared to JAK inhibitors, further data from Phase 3 trials and regulatory approvals are needed before a stronger recommendation can be made. Therefore, a 'hold' position allows investors to monitor further developments.

Keywords

Nektar Therapeutics, Rezpegaldesleukin, Alopecia Areata, REZOLVE-AA, Biologic, Treg, SALT Score, Clinical Trial